Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Celltrion, Inc.    A068270   KR7068270008


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Celltrion : Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers

09/14/2020 | 08:01am EST
COVID-19 antibody

Interim results from a Phase I clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody (mAb) treatment candidate, have been released. The results showed a promising safety, tolerability and pharmacokinetics profile of CT-P59.

Developed by Celltrion Group, CT-P59 was identified as a potential treatment for COVID-19 through screening of antibody candidates and selecting those that showed the highest potency in neutralising the SARS-CoV-2 virus including the mutated G-variant strain (D614G variant). In pre-clinical data the treatment candidate demonstrated a 100-fold reduction in viral load of SARS-CoV-2, as well as a reduction in lung inflammation.

The Phase I clinical trial is a randomised, double blind and placebo-controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P59 in healthy subjects. The results demonstrated no significant drug-related adverse events and importantly there were no adverse events from the maximum tolerated dose cohort.

"Along with these promising safety results, we have launched commercial production of CT-P59 this month to ensure, if trials are successful, we can meet the urgent global demand for a safe and effective antiviral treatment against COVID-19," said Dr Sang Joon Lee, Senior Executive Vice President of Celltrion. "Should we receive positive results from our series of ongoing clinical trials, we intend to request Emergency Use Authorisation (EUA) for our drug."

Celltrion has initiated an in-human, global, Phase I clinical trial of CT-P59 in mild COVID-19 patients and plans to conduct further global Phase II and III trials in 500 patients from 12 countries including Korea. Celltrion anticipates the enrolment of a total of 3,000 patients including those involved in the prevention clinical trial, investigating the use of CT-P59 as a preventative treatment for COVID-19 in those in close contact with COVID-19 patients. The company anticipates the development of the anti-COVID-19 mAb treatment candidate will be complete by the first half of 2021.

The post Phase I trial finds potential COVID-19 antibody treatment safe in healthy volunteers appeared first on European Pharmaceutical Review.

© Russell Publishing Limited, 2020. All Rights Reserved., source Trade Journals

All news about CELLTRION, INC.
11/06CELLTRION, INC. : quaterly earnings release
11/05Celltrion's COVID-19 antibody drug cut recovery time-early study
11/05CELLTRION HEALTHCARE : says Phase 1 trial shows COVID-19 antibody drug 'well-tol..
11/04S.Korea shares extend gains as investors eye tight U.S. election race
11/03S.Korea stocks gain most in nearly 5 months on strong global data
10/27S.Korea begins preliminary review of AstraZeneca's COVID-19 vaccine candidate
10/26S.Korea shares dip as surging global coronavirus cases dent sentiment
10/26South Korea pharma Celltrion's COVID test gets U.S. emergency use authorisati..
10/25S.Korea pharma Celltrion's COVID test gets U.S. emergency use authorisation
10/14CELLTRION : COVID-19 antibody treatment to enter Phase III trial
More news
Sales 2020 1 817 B 1,63 B 1,63 B
Net income 2020 563 B 0,51 B 0,51 B
Net cash 2020 449 B 0,40 B 0,40 B
P/E ratio 2020 71,7x
Yield 2020 0,00%
Capitalization 40 252 B 36 064 M 36 186 M
EV / Sales 2020 22 148x
EV / Sales 2021 18 758x
Nbr of Employees 908
Free-Float 68,3%
Duration : Period :
Celltrion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELLTRION, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 312 444,44 KRW
Last Close Price 301 000,00 KRW
Spread / Highest target 49,5%
Spread / Average Target 3,80%
Spread / Lowest Target -59,5%
EPS Revisions
Wu-Sung Ki Chief Executive Officer & Director
Jung-Jin Seo Chairman
Ho-Seop Lee Finance Director
Dong-Il Kim Independent Director
Joseph Lee Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.66.30%35 570
LONZA GROUP AG63.36%47 043
MODERNA, INC.399.03%38 625
SEAGEN INC.51.77%31 267
IMMUNOMEDICS, INC.315.22%20 324